Question:

Match the following pairs of vaccine and category/type:
a)Covaxin: Inactivated pathogen-based vaccine.
b)Covishield: mRNA Vaccine.
c)Sputnik V: Viral vector- based vaccine.

Show Hint

When learning about vaccines, make sure to differentiate between the various types, such as mRNA vaccines, inactivated vaccines, and viral vector-based vaccines.
Updated On: May 26, 2025
  • ‘a’ only.
  • ‘a’ and ‘b’ only.
  • ‘a’ and ‘c’ only.
  • ‘a’, ‘b’, and ‘c’.
Hide Solution
collegedunia
Verified By Collegedunia

The Correct Option is C

Approach Solution - 1

- Covaxin is an inactivated pathogen-based vaccine, which is option (a).
- Covishield is an adenoviral vector-based vaccine, not an mRNA vaccine as listed in option (b). Therefore, it is not part of the correct answer.
- Sputnik V is a viral vector-based vaccine, matching with option (c).
Thus, the correct answer is ‘a’ and ‘c’ only.
Was this answer helpful?
0
0
Hide Solution
collegedunia
Verified By Collegedunia

Approach Solution -2

The correct answer is ‘a’ and ‘c’ only, as explained below by matching each vaccine with its correct category/type:

a) Covaxin: Inactivated pathogen-based vaccine
This statement is correct. Covaxin is developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). It is an inactivated vaccine, which means it contains a killed version of the virus that causes COVID-19. This traditional approach triggers the immune system to recognize and respond to the virus without causing the disease.

b) Covishield: mRNA Vaccine
This statement is incorrect. Covishield, developed by AstraZeneca and manufactured by the Serum Institute of India, is a viral vector-based vaccine, not an mRNA vaccine. It uses a modified chimpanzee adenovirus to deliver genetic material that instructs cells to produce the spike protein of the SARS-CoV-2 virus, thus initiating an immune response.

c) Sputnik V: Viral vector-based vaccine
This statement is correct. Sputnik V, developed by the Gamaleya Research Institute in Russia, is also a viral vector-based vaccine. It uses two different human adenovirus vectors (Ad26 and Ad5) in two separate doses to deliver the genetic code for the spike protein and stimulate immunity.

Conclusion:
Only statements a and c are correct, making ‘a’ and ‘c’ only the right answer.
Was this answer helpful?
0
0

Questions Asked in TS LAWCET exam

View More Questions